BIOCAD
Sergei Niskanen is a highly experienced professional in research and development, currently serving as Research and Development Group Lead at BIOCAD since July 2018. Niskanen has successfully led projects, including the early development of therapeutic fusion proteins for cancer treatment and the development of BCD-261, a therapeutic antibody targeting Crohn’s disease and ulcerative colitis, which is now in clinical trials. Niskanen has a strong background in antibody engineering and vaccine development, having designed a WHO-listed SARS-CoV-2 polyepitope vaccine and developed diagnostic antibodies. Previous roles include positions at Innova Plus, the Institute of Cytology of the Russian Academy of Sciences, and the Centre of Laboratory Analysis and Technical Measurements, showcasing expertise in protein purification and environmental analysis. Niskanen holds a Master’s degree in Biochemistry and Molecular Biology from Saint Petersburg State University and a Specialist degree in Biology from Petrozavodsk State University.
This person is not in any teams
BIOCAD
6 followers
BIOCAD is Russia's leading innovative biotechnology company; it combines a world-class research and development center, ultra-modern pharmaceutical and biotechnological manufacturing facilities, as well as preclinical and clinical research infrastructure compliant with international standards. BIOCAD is one of the world`s few full-cycle drug development and manufacturing companies, from new molecule discovery and genetic engineering to large-scale commercial production and marketing support. BIOCAD`s medicines are dedicated to treat complex health conditions such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.